Organ preservation solution

A technology of organ preservation solution and compound, which is applied in the preservation, application, and animal husbandry of human or animal bodies. Effects of ischemia-reperfusion injury

Inactive Publication Date: 2017-09-08
SBI PHARMA CO LTD +1
View PDF16 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, since ascorbic acid disappears rapidly due to autooxidation (for example, see Non-Patent Document 1), it cannot be used as a component of organ preservation solutions. Research on ascorbic acid-type ascorbic acid in which the site related to the redox reaction is masked by bonding with glucose (for example, see Non-Patent Document 2)
It should be noted that ascorbic acid 2-glucoside is a prodrug that has no effect when it does not enter the cells. When it is actually used to preserve harvested organs, it may not be able to obtain the effect of organ preservation
[0006] On the other hand, although it has been reported that ascorbic acid can be stably present by adding ascorbic acid and ascorbyl phosphate at a specific concentration ratio to the medium for culturing cells (see, for example, Non-Patent Document 3), this result merely shows that Because ascorbic acid exists stably in cell culture, it does not reflect whether the extracted organs can maintain their function for a long time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Organ preservation solution
  • Organ preservation solution
  • Organ preservation solution

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] (preparation of preservation solution)

[0082] Three freshly prepared organ preservation solutions (preservation solution (a) to preservation solution (c)) were used as research objects. Details of components added and dissolved in distilled water are shown in Table 1 below. When an organ for transplantation is immersed in the above-mentioned preservation solution beyond the maximum allowable ischemia time specified for the conventional preservation solution product, it is examined whether the function of the organ can be maintained after transplantation. Specifically, when the hearts of donor mice immersed in the above three types of preservation solutions were transplanted into mice of the same strain, the time elapsed after the transplantation until the start of beating again was used as an index. In order to conduct a comparative study, three kinds of preservation solutions that are known as existing products, namely Euro-Collins solution (EC solution), histidine-...

Embodiment 2

[0096] (Mice Heterotopic Heart Transplantation 2)

[0097] The immersion time in each preservation solution was set to 48 hours, and the existing products HTK solution and EC solution were used for comparative study, and the procedure of the above-mentioned Example 1 (heterotopic heart transplantation in mice 1) was followed. Heterotopic heart transplantation in mice was performed. The elapsed time until the transplanted heart started beating was measured for each individual mouse to which a heterotopic heart was transplanted. The results are shown in figure 2 middle.

[0098] (result 2)

[0099] Depend on figure 2 It can be seen that the re-beating start time of HTK solution and EC solution is more than 1500 seconds. On the other hand, the re-beating start time of preservation solution (a) is about 500 seconds, and the re-beating start time of preservation solution (b) is 1250 seconds. On the other hand, the re-beating start time of the preservation solution (c) was ab...

Embodiment 3

[0101] (Mice Heterotopic Heart Transplantation 3)

[0102] As a series of iron-added preservation solutions, a preservation solution (d) in which ferrous sulfate was added to the above-mentioned preservation solution (c) was further prepared, and research was continued. The details of the components of each preservation solution are shown in Table 3 below.

[0103] [table 3]

[0104]

[0105] As the iron-added series of preservation solutions, preservation solution (d) 3 and preservation solution (d) 6 were used, and the existing product UW solution was used for comparative research. The procedure of heart transplantation 1) performed heterotopic heart transplantation in mice. After immersion in the preservation solution for 24 hours, the time elapsed until the transplanted heart started beating was measured for each individual mouse to which the heterotopic heart was transplanted. The results are shown in image 3 middle.

[0106] Furthermore, after the heart transpla...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided is an organ preservation solution for use in transplants which can effectively prevent the occurrence of ischemia reperfusion injury. An organ preservation solution is prepared which contains a blend of the following components: (a) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphoric acid ester and D-glucose; (b) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphoric acid ester, glycine, and D-glucose; (c) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphoric acid ester, L-cysteine, glycine, and D-glucose; or (d) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphoric acid ester, L-cysteine, glycine, iron compound and D-glucose.

Description

technical field [0001] The present invention relates to an organ preservation solution, and more specifically, to an organ preservation solution prepared by blending L-ascorbic acid and L-ascorbic acid phosphate. Background technique [0002] Organ preservation solutions are known as liquids for perfusing and soaking resected organs at the time of organ transplantation. If the blood flow is interrupted for a long time, the organs in the living body will fall into necrosis. Therefore, although various methods have been developed for transporting the harvested organs for transplantation for a long time, the simple cooling method is the most clinically used method . An organ preservation solution is mainly used in this simple cooling method. For harvested organs, necrosis is prevented by perfusing with the organ preservation solution and immersing in the same cooled organ preservation solution after harvest. [0003] Currently, organ preservation solutions commonly used in c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A01N1/02
CPCA01N1/0226A01N1/02
Inventor 田中彻中岛元夫太田丽伊东秀典梨井康
Owner SBI PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap